Totally plc
("Totally", "the Company" or
"the Group")
Interim results for the six
months ended 30 September 2024
Good progress with new
contracts secured and improved profitability
Totally plc (AIM: TLY), a leading
provider of frontline healthcare services, corporate fitness
and wellbeing services across the UK and Ireland, is
pleased to announce its unaudited interim results for the six
months ended 30 September 2024.
Financial highlights
•
Revenue in line with the Board's expectations at
£41.7 million (H1 2024: £55.8 million; H2 2024: £50.9
million).
•
Gross margin consistent with the comparative half year at 17.3% (H1
2024: 17.4%).
•
Underlying EBITDA before exceptional items increased by 5%
to £1.2 million (H124: £1.1
million).
•
EBITDA before exceptional items as a percentage of revenue at 2.8%
(H1 2024: 2.0%).
•
Improved profit performance delivering a break-even profit after
tax (H1 2024: £1.9 million loss before
tax).
• Gross cash of £1.4
million as at 30 September 2024 (30
September 2023: £1.7 million;
31 March 2024: £2.3 million).
• Debt
remains unchanged at £2.5 million.
• RCF
renewed for a further two years at £3.5 million, as announced on 31
October 2024.
Operational highlights
· Six
new contracts confirmed at a value of c.£7.5 million to be realised
in the current financial year.
· A
further 14 contracts renewed at a total value of c. £19
million
· Totally continues to support the NHS and healthcare providers
across the UK and in the Republic of
Ireland with the delivery of urgent and elective care services
across multiple locations, ensuring that patients can access the
appropriate care, when they need it.
· New
insourcing contract mobilised in the North of England, ensuring
patients with long waits for elective procedures receive treatment
as soon as possible.
· Energy
Fitness Professionals mobilised their largest contract to date at a
value of £0.5 million.
· All
Care Quality Commission (CQC) registerable services continue to be
rated as GOOD reflecting Totally's commitment to excellent patient
care during continued pressure across the healthcare
industry.
Chair's statement
I am pleased to announce Totally's
trading results for the six months ended 30 September 2024.
The actions taken in the last financial year have led to an
improved financial position versus that reported for the year
ending 31 March 2024 with revenues in line with the guidance issued
at the 2024-year end and improved margins. The operating
environment continues to be challenging, but we are beginning to
see the benefits of those actions. We focused on increasing
the profitability of our contracts reflected by the delivery of
EBITA slightly ahead of prior year despite reduced revenues.
I am also pleased to report a return to profitability with a modest
profit before tax being reported.
During the first half of the year,
we continued to tender for opportunities to run urgent care
services on behalf of the NHS and to reduce elective care waiting
lists through both insourcing and outsourcing. Most
significantly we won a new contract in the North of England to
support patients with long waits for elective care. This
contract has been mobilised and patient and commissioner feedback
is positive. Performance across our urgent care services
remains strong with an exceptional performance delivered on behalf
of NHS England as part of the ongoing NHS 111 resilience contract.
As we enter the seasonally busier winter months, these services
will be important in ensuring patients can continue to access the
support they need.
I would like to share my thanks with
our hardworking teams, who continue to deliver essential services
alongside their NHS colleagues, and to our shareholders, who have
supported Totally plc as we turn the business back to
profitability. I believe that we are a stronger and
more resilient organisation than we were a year ago, and have
confidence that we can now respond positively to new opportunities
and begin to grow the business once again.
Simon Stilwell
Chair
6 November
2024
Operational review
During the first half of the year,
we have continued to realise the benefit of actions taken to
respond to the difficult operating environment, increase
accountability and improve performance and we are pleased to
announce that we are on track to deliver against forecasts for the
current financial year.
Revenue in the first half of the
year was lower than in previous quarters but in line with the
Board's expectations at £41.2 million (H1 2024: £55.8 million; H2
2024: £50.9 million) and although profit realisation remains
challenging due to continued wage pressures, profitability has
improved. EBITDA before exceptional items was resilient at
£1.2 million (H1 2024: £1.1 million, H2 2024: £1.1 million) and we
achieved a small profit before tax, a significant improvement from
the previous period (H1 2024: £1.8 million loss before tax; H2 2024
£2.0 million loss before tax). Cash at the end of September
was £1.4 million (31 March 2024 £2.3 million) and we have now
completed the renewal of the Revolving Credit Facility ("RCF") as
announced on 31 October 2024, which has been renewed for a further
two years at a level of £3.5 million reflecting the current size of
the business. Draw down against the RCF remains unchanged at
£2.5 million. We continue to manage costs
proactively.
Following the election of the new
government, we have seen a slight improvement in the market and the
pipeline of new opportunities to review is healthy. As part
of the Autumn Budget 2024, the government allocated an extra £25.7
billion to the NHS over 2024 and 2025. Some of this
additional funding will target the delivery of an extra 40,000
elective appointments a week to help reduce waiting times and we
anticipate further opportunities to arise as this funding,
alongside increased clarity on targets for the coming year, becomes
available. Further guidance and a new 10-year plan is expected in
late Spring 2025. The Board view this funding as positive for
the prospects of the Company.
The Group has also reviewed other
implications of the recent budget. As part of its
forecasting, the Board had anticipated some change in the national
minimum wage. While the reduction in national insurance threshold
was not anticipated, and given the changes only take effect from
April 2025, the Group will endeavour to mitigate the impact of
these including delivering further efficiencies, savings and some
contractual mechanisms in the financial year.
The opportunity to work with the NHS
remains attractive. During the period we announced six new
contract wins across elective care totalling c. £7.5 million
including a new sizeable contract for the delivery of insourcing
services in the North of England valued at c. £5 million, all of
which will be recognised in the current financial
year. A further 14 contracts were
renewed at a total value of c. £19 million.
In Corporate Wellbeing we mobilised
the new contract to deliver services in the City and we are seeing
existing customers investing in new trends within the market such
as Paddle Courts.
The second half of the year is
traditionally busier as we move into the winter season and we
expect this year to be no different. Record attendances at
A&E across the NHS during September alongside an expected
resurgence of Covid, flu and RSV (Respiratory syncytial virus)
indicate an incredibly busy winter within healthcare.
The delivery of UTCs is a model which supports the
reduction of waiting times by streaming patients to the most
appropriate care and within UTCs managed by Totally, 93% of
patients were transferred or discharged within four hours, ensuring
patients receive the care they need as quickly as possible and
supporting overall A&E KPI for the Trusts with which we
work. Within NHS 111 we consistently
outperformed the national service average and placed in the top
three providers in the country for calls answered within 60 secs,
abandonment rates, and for patients receiving a call back from a
clinician within 20 mins. During October 98.8% of patients'
calls were answered within 60 seconds and 78.6% of patients
requiring a clinician call back are receiving that call within 20
mins, versus a national average of 39.9%.
Focus also continues on the
reduction of waiting lists and new contracts for insourcing and
outsourcing will support this effort. Overall, some 7.6
million patients await treatment with c. 280,000 people in England
waiting more than 52 weeks to start routine hospital treatment at
the end of August. The new contract for insourcing in the North of
England is specifically targeting those with waits of more than 52
weeks.
Outlook
The healthcare market continues to
face significant challenges but we have continued to focus on what
we can control to ensure quality services for patients, value for
money for commissioners, and appropriate returns for
investors.
We are confident that our strong
cost management culture and most robust organisation will deliver
this year's market guidance.
The Board has increased confidence
in the near to long term prospects of the business and we remain
confident that the business is well-positioned for growth.
We look forward to the publication of the
Government's 10-year health plan for the NHS, due in Spring 2025
and believe that with correct funding, independent healthcare
providers will be able to play a key role to play in tackling the
challenges faced by the NHS, once and for all.
In the meantime, we continue to
support NHS organisations to address their individual needs and
take actions to improve patient access to services and provide high
quality services for all commissioned services.
I would like to thank our team for
their continued hard work and commitment.
Wendy Lawrence
Chief Executive Officer
6 November
2024
Investor presentation
Wendy Lawrence, Chief Executive
Officer and Laurence Goldberg, Chief Financial Officer will provide
a live presentation relating to the
Company's interim results via the Investor Meet Company at 11.00
a.m. (UK) on Thursday, 7 November 2024. The online presentation is open to all existing and potential
shareholders and will consist of a presentation followed by a
Q&A session. Questions can be submitted pre-event via
the Investor Meet Company dashboard or at any time during
the live presentation.
Investors can sign up
to Investor Meet Company for free and add to
meet Totally plc via:
https://www.investormeetcompany.com/totally-plc/register-investor
Investors who already
follow Totally plc on the Investor Meet
Company platform will automatically be invited.
For
further information please contact:
Totally plc
Wendy Lawrence, Chief
Executive Officer
Simon Stilwell, Chair
|
020 3866
3330
|
Canaccord Genuity Limited (Nominated Adviser & Corporate
Broker)
Bobbie Hilliam / Harry
Rees
|
020 7523
8000
|
Notes to editors
About Totally
Totally is a leading provider of
healthcare and wellbeing services across
the UK and Ireland, working in partnership with the
NHS, other healthcare providers and corporate customers to help
address the challenges of increased demand for healthcare
services.
Totally helps healthcare
commissioners and hospitals ensure patients can access the most
appropriate care quickly and efficiently by delivering quality
urgent care services, such as NHS 111 and urgent treatment centres,
elective care services including insourcing, outsourcing and
elective care delivered via 'Any Qualified provider', as well as
community dermatology clinics; and therapy servicing including
first contact practitioner and a full physiotherapy and podiatry
offering. Our corporate customer services also play a role in
reducing reliance on healthcare by promoting healthy lifestyles and
physical and mental health.
Healthcare services
Urgent Care: Totally's urgent care services
are delivered under the Totally Urgent Care brand, by Vocare
and Greenbrook Healthcare. Both businesses have a strong heritage
and have been delivering quality urgent care services including NHS
111, GP Out of Hours and Urgent Treatment centres on behalf of the
NHS for more than 25 years and 15 years respectively.
Elective care: Totally's elective care services
are delivered by Pioneer Healthcare, About Health and Premier
Physical Healthcare.
· Pioneer Healthcare was established in 2007 and delivers a wide
range of acute services to NHS patients, in partnership with
independent healthcare sector private hospitals
across England, to help the NHS reduce waiting lists whilst
maintaining patient care and quality. Pioneer offer services
through insourcing and outsourcing agreements and through its Any
Qualified Provider status.
· About
Health has been delivering community-based specialist care with a
focus on delivering prompt assessment and treatment across the
country since 2008.
· Premier Physical Healthcare was established in 2007 and
provides physiotherapy and podiatry services to NHS patients, often
within a community GP practice, and to the prison
service.
Corporate Wellbeing Services
Energy Fitness Professionals
("EFP"): EFP is a corporate fitness provider established in 1990 to
address a gap in the market for workplace fitness, which has grown
to offer a range of services covering workplace wellbeing. EFP
manages 62 gyms on behalf of its corporate customers, with more
than 13,000 members.
For more information
visit www.totallyplc.com
Interim Consolidated Income Statement
For the six months ended 30 September
2024
|
|
|
|
|
|
Six Months ended 30
September 2024
(unaudited)
£000
|
Six Months ended 30
September 2023
(unaudited)
£000
|
Year ended 31 March
2024
(audited)
£000
|
Revenue
|
41,706
|
55,802
|
106,678
|
Cost of sales
|
(34,479)
|
(46,114)
|
(88,947)
|
Gross profit
|
7,227
|
9,688
|
17,731
|
Administrative expenses
|
(6,054)
|
(8,569)
|
(15,855)
|
Other income
|
-
|
-
|
387
|
EBITDA before exceptional items
|
1,173
|
1,119
|
2,263
|
Exceptional items
|
(42)
|
(475)
|
(874)
|
EBITDA
|
1,131
|
644
|
1,389
|
Depreciation and
amortisation
|
(939)
|
(2,254)
|
(4,867)
|
Operating profit
|
192
|
(1,610)
|
(3,478)
|
Finance costs
|
(187)
|
(257)
|
(387)
|
Profit before tax
|
5
|
(1,867)
|
(3,865)
|
Income tax credit
|
-
|
-
|
731
|
Profit after tax
|
5
|
(1,867)
|
(3,134)
|
|
|
|
|
|
|
|
|
Earnings per
share
|
|
|
|
Basic: Pence
|
0.00
|
(0.95)
|
(1.60)
|
Diluted: Pence
|
0.00
|
(0.95)
|
(1.60)
|
Adjusted Earnings per
share
|
|
|
|
Basic: Pence
|
0.02
|
(0.50)
|
1.09
|
Diluted: Pence
|
0.02
|
(0.50)
|
1.09
|
All activities relate to continuing
operations.
Interim Consolidated Statement of Changes in Equity
For the six months ended 30 September 2024
|
Share
capital
£000
|
Share
premium
£000
|
Retained
earnings
£000
|
Equity Shareholders'
funds
£000
|
At
1 April 2024 (Audited)
|
19,655
|
1,945
|
12,130
|
33,730
|
Comprehensive profit for the period
(Unaudited)
|
-
|
-
|
5
|
5
|
|
|
|
|
|
At
30 September 2024 (Unaudited)
|
19,655
|
1,945
|
12,135
|
33,735
|
|
|
|
|
|
At 1 April 2023 (Audited)
|
19,610
|
1,945
|
15,510
|
37,065
|
Comprehensive loss for the period
(Audited)
|
-
|
-
|
(3,134)
|
(3,134)
|
Issue of shares, net of share issue
expenses (Audited)
|
45
|
-
|
-
|
45
|
Dividend payment
(Audited)
|
-
|
-
|
(246)
|
(246)
|
|
|
|
|
|
At 31 March 2024 (Audited)
|
19,655
|
1,945
|
12,130
|
33,730
|
|
|
|
|
|
At 1 April 2023 (Audited)
|
19,610
|
1,945
|
15,510
|
37,065
|
Comprehensive loss for the period
(Unaudited)
|
-
|
-
|
(1,867)
|
(1,867)
|
Issue of share capital, net of share
issue expenses
|
45
|
-
|
-
|
45
|
At 30 September 2023 (Unaudited)
|
19,655
|
1,945
|
13,643
|
35,243
|
Interim Consolidated Statement of Financial
Position
As at 30 September 2024
|
30 September
2024
(unaudited)
£000
|
30 September
2023
(unaudited)
£000
|
31 March
2024
(audited)
£000
|
Non-current assets
|
|
|
|
Intangible fixed assets
|
46,057
|
46,641
|
45,809
|
Property, plant and
equipment
|
938
|
1,107
|
1,114
|
Right-of-use assets
|
2,003
|
2,689
|
2,308
|
Deferred tax
|
560
|
242
|
560
|
Total non-current assets
|
49,558
|
50,679
|
49,791
|
Current assets
|
|
|
|
Inventories
|
54
|
72
|
53
|
Trade and other
receivables
|
9,669
|
16,609
|
11,147
|
Cash and cash equivalents
|
1,379
|
1,704
|
2,341
|
Total current assets
|
11,102
|
18,385
|
13,541
|
Total assets
|
60,660
|
69,064
|
63,332
|
Current liabilities
|
|
|
|
Trade and other payables
|
(21,633)
|
(26,753)
|
(24,061)
|
Borrowings
|
(2,500)
|
(2,500)
|
(2,500)
|
Lease liabilities
|
(595)
|
(508)
|
(578)
|
Contingent consideration
|
-
|
(528)
|
-
|
Total current liabilities
|
(24,728)
|
(30,289)
|
(27,139)
|
Non-current liabilities
|
|
|
|
Lease liabilities
|
(1,625)
|
(2,311)
|
(1,891)
|
Other payables
|
(12)
|
(209)
|
(12)
|
Deferred tax
|
(560)
|
(1,012)
|
(560)
|
Total non-current liabilities
|
(2,197)
|
(3,532)
|
(2,463)
|
Total liabilities
|
(26,925)
|
(33,821)
|
(29,602)
|
Net
current liabilities
|
(13,626)
|
(11,904)
|
(13,598)
|
Net
assets
|
33,735
|
35,243
|
33,730
|
|
|
|
|
Shareholders' Equity
|
|
|
|
Share capital
|
19,655
|
19,655
|
19,655
|
Share premium account
|
1,945
|
1,945
|
1,945
|
Retained earnings
|
12,135
|
13,643
|
12,130
|
Equity shareholders' funds
|
33,735
|
35,243
|
33,730
|
Interim Consolidated Cash Flow Statement
For the six months ended 30
September 2024
|
Six Months ended 30
September 2024
(unaudited)
£000
|
Six Months
ended 30 September
2023
(unaudited)
£000
|
Year ended 31 March
2024
(audited)
£000
|
Cash flow from operating activities:
|
|
|
|
Profit/(Loss) before tax
|
5
|
(1,867)
|
(3,865)
|
Adjustments for:
|
|
|
|
Amortisation and
depreciation
|
939
|
2,254
|
4,867
|
Loss on disposal of
non-current assets
|
-
|
-
|
(25)
|
Finance
Income
|
-
|
-
|
(27)
|
Finance
costs
|
187
|
257
|
414
|
Movements in working capital:
|
|
|
|
Movement in
inventory
|
(1)
|
3
|
22
|
Movement in trade and
other receivables
|
1,478
|
(2,929)
|
2,467
|
Movement in trade and
other payables
|
(2,354)
|
(1,554)
|
(4,517)
|
Cash generated from/(used in) operations
|
254
|
(3,836)
|
(664)
|
Income tax
received/(paid)
|
-
|
-
|
-
|
Net
cash flows from operating activities
|
254
|
(3,836)
|
(664)
|
|
|
|
|
Cash flow from investing activities:
|
|
|
|
Purchase of property, plant and
equipment
|
(108)
|
(224)
|
(636)
|
Disposal of property, plant and
equipment
|
-
|
-
|
29
|
Additions of intangible
assets
|
(578)
|
(114)
|
(1,013)
|
Contingent consideration
|
-
|
-
|
(312)
|
Net
cash flows from investing activities
|
(686)
|
(338)
|
(1,932)
|
|
|
|
|
Cash (outflow)/inflow before financing
|
(432)
|
(4,174)
|
(2,596)
|
|
|
|
|
Cash flow from financing activities:
|
|
|
|
Issue of share capital
|
-
|
45
|
45
|
Dividends paid
|
-
|
-
|
(246)
|
Interest paid
|
(187)
|
(188)
|
(218)
|
Finance lease payments
|
(343)
|
(430)
|
(1,095)
|
Net
cash flow from financing activities
|
(530)
|
(573)
|
(1,514)
|
|
|
|
|
Net
decrease in cash and cash equivalents
|
(962)
|
(4,747)
|
(4,110)
|
Cash and cash equivalents at
beginning of the period
|
2,341
|
6,451
|
6,451
|
Cash and cash equivalents at end of the
period
|
1,379
|
1,704
|
2,341
|
Notes to the Interim Results
1.
Basis of preparation
Totally plc is a public limited
company incorporated in the United Kingdom under the
Companies Act 2006 (registration number: 3870101). The Company's
ordinary shares are admitted to trading on the AIM market of
the London Stock Exchange ("AIM").
The Group's principal activities in
the period under review have been the provision of innovative and
consolidatory solutions to the healthcare sector, which are
provided by the Group's wholly owned subsidiaries.
The consolidated financial
statements have been prepared in accordance with UK-adopted
International Accounting Standards and with the requirements of the
Companies Act 2006 as applicable to companies reporting under those
standards.
The interim report and condensed
financial statements have been prepared on the basis of the
accounting policies, presentation and methods of computation as set
out in the Group's March 2024 Annual Report and Accounts
and on the basis of the principal accounting policies that the
Group expects to apply in its financial statements for the year
ending 31 March 2025.
The interim report and condensed
financial statements do not comprise statutory accounts within the
meaning of section 434 of the Companies Act 2006. These interim
financial statements were approved by the Board of
Directors on 5 November. The results
for the six months to 30 September 2024 and the
comparative results for the six months to 30 September
2023 are unaudited. The amounts for the period
ended 31 March 2024 are extracted from the audited
statutory financial statements of the Group for
that period.
The Directors have considered the
financing needs for the Group for the period to 31 December 2025
taking into account the risks and uncertainties referred to in the
2024 Annual Report. This assessment considered reasonably plausible
downsides and measured these against available cash resources and
the recently renewed RCF. The directors have concluded that the
Group is a going concern for the period to 31 December 2025, and
that therefore the going concern basis of preparation continues to
be appropriate.
2. Earnings per
share
Basic earnings per share is
calculated by dividing the (loss)/profit attributable to equity
holders of the Company by the weighted average number of ordinary
shares in issue during the period. Diluted earnings per share takes
into account the effects of share options in issue.
Adjusted earnings per share is
calculated by dividing the pre-exceptional (loss)/profit before
amortisation of intangible customer contracts & relationships
and tax by the weighted average number of ordinary shares in issue
during the period.
Statutory Earnings per share
|
6 months
ended
30 September
2024
£000
(Unaudited)
|
6 months
ended
30 September
2023
£000
(Unaudited)
|
Year ended 31 March
2024
£000
(Audited)
|
|
|
Profit/(Loss) (£000)
|
5
|
(1,867)
|
3,134
|
|
|
Weighted average number of shares
used in basic earnings per share calculations ('000)
|
196,547
|
196,547
|
196,464
|
|
|
Potentially dilutive share options
and contingent share consideration ('000)
|
-
|
144
|
15
|
|
|
Weighted average number of shares
used in diluted earnings per share calculations ('000)
|
196,547
|
196,691
|
196,479
|
|
|
Basic earnings per share
(Pence)
|
0.00
|
(0.95)
|
1.60
|
|
|
Diluted earnings per share
(Pence)
|
0.00
|
(0.95)
|
1.60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Adjusted Earnings per share
|
6 months
ended
30 September
2024
£000
(Unaudited)
|
6 months
ended
30 September
2023
£000
(Unaudited)
|
Year ended 31 March
2024
£000
(Audited)
|
|
Pre-exceptional profit before tax
(£000)
|
47
|
(1,867)
|
2,346
|
|
Amortisation of intangible customer
contracts & relationships
|
-
|
880
|
850
|
|
Adjusted profit (£000)
|
47
|
(987)
|
(2,141)
|
|
Weighted average number of shares
used in diluted earnings per share calculations ('000)
|
196,547
|
196,547
|
196,464
|
|
Potentially dilutive share options
and contingent share consideration ('000)
|
-
|
144
|
15
|
|
Weighted average number of shares
used in diluted earnings per share calculations ('000)
|
196,547
|
196,691
|
196,479
|
|
Adjusted basic earnings per share
(Pence)
|
0.02
|
(0.50)
|
(1.09)
|
|
Adjusted diluted earnings per share
(Pence)
|
0.02
|
(0.50)
|
(1.09)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
3. Dividends
No interim dividend proposed (H124:
nil).